Kay A B, Diaz P, Carmicheal J, Grant I W
Clin Exp Immunol. 1981 Jun;44(3):576-80.
Monocyte complement receptors (MCR) and enhancement of MCR by a monocyte chemotactic factor (casein) (CRE) were measured in corticosteroid-resistant and corticosteroid-responsive chronic asthmatics. In newly-diagnosed patients who subsequently responded to corticosteroids, the percentage of MCR and CRE was lower after taking oral prednisolone for 7 days and returned to pretreatment values when prednisolone was withdrawn. MCR and CRE in corticosteroid-responsive asthmatics receiving prednisolone were significantly lower than in corticosteroid-resistant asthmatics taking prednisolone. However, there was no significant difference in MCR and CRE between non-responders taking prednisolone and non-responders receiving other forms of therapy. These results suggest that one of the effects of systemic corticosteroids in asthmatics who respond to this form of treatment is a decrease in both MCR and the degree of CRE. Since these changes were not found in corticosteroid-resistant chronic asthmatics such patients may have a defect in the expression and mobilization of complement receptors on the monocyte cell membrane.
在皮质类固醇抵抗型和皮质类固醇反应型慢性哮喘患者中，检测了单核细胞补体受体（MCR）以及单核细胞趋化因子（酪蛋白）对MCR的增强作用（CRE）。在新诊断的、随后对皮质类固醇有反应的患者中，口服泼尼松龙7天后，MCR和CRE的百分比降低，停用泼尼松龙后又恢复到治疗前水平。接受泼尼松龙治疗的皮质类固醇反应型哮喘患者的MCR和CRE显著低于接受泼尼松龙治疗的皮质类固醇抵抗型哮喘患者。然而，服用泼尼松龙的无反应者和接受其他治疗形式的无反应者之间的MCR和CRE没有显著差异。这些结果表明，全身皮质类固醇对这种治疗形式有反应的哮喘患者的作用之一是MCR和CRE程度均降低。由于在皮质类固醇抵抗型慢性哮喘患者中未发现这些变化，此类患者可能在单核细胞膜上补体受体的表达和动员方面存在缺陷。
